Pfizer – Request for Proposals (RFP) Quality Improvement Grants to Improve Identification and Management of Patients with ATTR-CM in Canada

Governance and Public Policy
Well-being, Health and Biomedical Discovery


Academic Unit: inquire with unit

Memorial Deadline: Wednesday 13th, April 2022

External Deadline: Tuesday 19th, April 2022


Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the practice gaps as outlined in the specific RFP.

For all independent quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program.

Geographic Scope: Canada
Clinical Area: Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Link to full RFP: Quality Improvement Grants to Improve Identification and Management of Patients with ATTR-CM in Canada
Application Due Date: April 6, 2022
Grant Application Due Date Extended: April 19, 2022

Specific Area of Interest: Projects that will be considered for Pfizer support will focus on improving the identification and management of ATTR-CM patients by providing leadership, best practices, novel clinical pathways, support and/or training of HCPs within a multidisciplinary team environment in order to improve the quality of care for patients with ATTR-CM.

Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Amanda Stein, Grant Officer (

Funding Sources

Pfizer Inc

This opportunity was posted by: RGCS

Last modified: April 6, 2022